



Epi Database®

The most trusted industry resource

At a glance

Epi Database® is the gold standard of reliable epidemiological data, providing unsurpassed breadth of coverage, including:

- 230 indications and growing
- Over 1,500 subgroups (including severity and treatment)
- 21 therapeutic areas
- 13 countries, including key emerging markets with functionality to extrapolate globally

Reliable epidemiological data is the first place to start for key management decisions regarding your products.

Epi Database® is the gold standard of epidemiology data, providing reliable, rigorous research and documentation in US, UK plus EU4, Japan, China, Brazil, India, Russia, Mexico, and Turkey.

In-depth analysis with projections to 2055

Epi Database® provides data spanning from 2015 to 2055. Epidemiology analyses are segmented by country, indication and year, as well as by gender, race, and age, if applicable. All data in Epi Database® are thoroughly researched by a team of trained epidemiologists; utilizes scientific literature and/or public and private data sources; and is fully documented to ensure complete transparency.

Epi Database® includes rare disease

As a benefit to our clients, Epi Database® includes data on a wide range of rare diseases with new diseases added each quarter based on our users' requests. Our team has extensive experience in understanding the challenges and complexities in determining rare and ultra-rare disease population estimates.

Trusted for major product decisions

Our clients have used Epi Database® to propel their business by:

- Quantifying market potential
- Prioritizing additional indications for in-line products
- Assessing licensing opportunities
- + Prioritizing drug discovery
- Understanding unmet needs of previously untapped markets

Impactful data visualization

New dashboards include:

- Rank order indications by market size
- World map comparing prevalence across countries
- Detailed patient segment charts
- Prevalence funnel
- Compare prevalence and incidence rates across markets and across indications

Custom epidemiology analysis

Epidemiologies for indications not included in Epi Database® can be completed on a custom basis to provide detailed patient populations using customized data approaches

ORACLE



Epi Database®

Epi Database® is delivered via a user-friendly online portal with data exportable to Microsoft Excel.

Visual comparison of cross-country differences

Detailed view of disease segments and patient characteristics

Compare across indications and geographies at the same time



Asthma - United States (Epidemiology/Diagnosed Prevalence) [Updated:12/11/2019]

Available Information Data Chart Description Sources
 GT Asthma Summary Table pptx

Gender: Male Female Both
 Age Cohort: 0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+ Total

Cohorts	2010	2011	2012	2013	2014	2015	2016	2017	2018
0-4	1,230,327	1,373,269	1,064,855	825,640	848,991	935,162	941,397	947,004	953,734
5-9	2,157,081	1,952,753	2,170,997	1,852,855	2,060,096	1,838,227	1,830,722	1,819,858	1,810,193
10-14	2,193,282	2,352,354	2,177,219	2,227,420	2,153,595	2,195,088	2,192,658	2,207,703	2,218,698
15-19	2,060,758	2,038,527	2,328,047	1,760,934	1,912,266	2,107,000	2,110,192	2,107,013	2,105,808
20-24	2,037,019	1,797,794	1,910,645	1,584,958	1,890,080	1,655,313	1,992,587	1,498,422	1,489,290
25-29	1,627,620	1,688,588	1,670,434	1,303,014	1,636,944	1,553,042	1,739,304	1,775,526	1,796,270
30-34	1,395,005	1,649,936	1,605,293	1,460,884	1,496,397	1,363,355	1,347,773	1,535,960	1,551,776
35-39	1,527,349	1,265,163	1,377,697	1,271,771	1,271,965	1,467,374	1,544,481	1,467,662	1,494,454
40-44	1,518,862	1,626,100	1,482,114	1,243,517	1,395,390	1,488,909	1,719,459	1,524,469	1,535,176
45-49	1,717,467	1,696,815	1,621,038	1,664,723	1,464,270	1,727,512	1,784,030	1,636,664	1,627,707
50-54	1,911,323	1,903,613	1,826,306	1,542,308	1,467,549	1,693,258	2,526,695	1,935,901	1,895,649
55-59	1,617,533	1,715,797	1,774,379	1,665,179	1,760,819	1,803,753	1,900,413	1,647,082	1,647,662
60-64	1,496,971	1,768,191	1,639,413	1,526,246	1,537,078	1,726,033	1,739,218	1,822,465	1,900,915
65-69	1,057,631	1,068,556	1,145,792	954,249	1,054,920	1,086,494	1,415,947	1,272,785	1,297,047
70-74	611,160	790,304	693,376	602,261	693,924	604,196	647,814	637,765	681,210
75-79	685,034	552,368	643,067	531,272	641,540	491,432	632,124	643,643	683,624
80-84	369,451	429,474	279,322	296,475	268,343	345,662	303,264	308,993	317,636
85+	216,538	221,616	264,605	254,649	228,615	350,811	229,655	263,407	266,123
Total	25,632,211	25,861,278	25,574,421	22,648,355	24,008,983	24,632,621	26,597,733	25,374,422	25,553,411



Indication	%	Germany	France	Italy	Japan	Spain	United Kingdom	United States	Brazil	China	India	Russian Federation	EM (Mexico, Turkey)
Acute Coronary Syndrome	4.3%	1.5%	2.7%	1.5%	3.1%	3.5%	1.1%	7.5%	17.9%	18.5%	7.1%	7.5%	
Alzheimer's Disease	5.7%	5.0%	5.3%	4.4%	6.4%	5.1%	0.3%	3.9%	3.0%	1.5%	2.4%	10.6%	
Asthma	11.4%	11.3%	11.3%	1.0%	11.4%	11.6%	13.6%	21.0%	22.0%	15.1%	18.4%	45.7%	
Diabetes Mellitus Type 2	17.8%	20.4%	14.7%	35.7%	18.9%	22.3%	30.9%	21.0%	22.0%	15.1%	18.4%	45.7%	
Hypertension	28.1%	17.4%	20.3%	25.8%	18.5%	14.0%	35.3%	27.6%	21.0%	15.1%	18.4%	45.7%	
Ischemic Heart Disease	4.7%	8.1%	15.6%	4.5%	10.9%	6.7%	10.8%	5.7%	2.4%	1.2%	6.5%	1.9%	
Stroke	4.7%	8.1%	15.6%	4.5%	10.9%	6.7%	10.8%	5.7%	2.4%	1.2%	6.5%	1.9%	
Tuberculosis	0.4%	0.4%	0.4%	0.4%	0.4%	0.4%	0.5%	0.4%	0.4%	0.4%	0.4%	0.4%	
Unlabeled	0.4%	0.4%	0.4%	0.4%	0.4%	0.4%	0.5%	0.4%	0.4%	0.4%	0.4%	0.4%	
Other	28.1%	17.4%	20.3%	25.8%	18.5%	14.0%	35.3%	27.6%	21.0%	15.1%	18.4%	45.7%	

About Oracle Life Sciences

Oracle Life Sciences is a leader in cloud technology, pharmaceutical research, and consulting, trusted globally by professionals in both large and emerging companies engaged in clinical research and pharmacovigilance, throughout the therapeutic development lifecycle, including pre- and post-drug launch activities.

With more than 20 years' experience, Oracle Life Sciences is committed to supporting clinical development and leveraging real-world evidence to deliver innovation and accelerate advancements – empowering the Life Sciences industry to improve patient outcomes.

Learn more at oracle.com/lifesciences

Copyright © 2024 Oracle and/or its affiliates. All rights reserved.

3048939605_Epi Database Factsheet 2024